Category Archives: Patently BIOtech

CNBC Commentary: Hedge funds, ‘reverse trolls’ crushing biopharma innovation

Vote No on HR 9

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to perform the long and costly research and development for cures and therapies to combat devastating diseases such as cancer, HIV and Alzheimer’s. Unfortunately, the system that helps protect these innovations is being abused by outside interests. BIO and others have called upon Congress to fix these problems as part of a greater patent reform debate. Today one more voice joined Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Understanding the Wider Implications of HR 9: Patent Reform’s Impact on Agriculture

US_Patent_And_Trademark_Office

The House Judiciary Committee recently approved H.R. 9, the Innovation Act, legislation they hoped would reduce frivolous patent-related litigation, frequently filed by so-called “patent trolls.”  Unfortunately, rather than surgically targeting abusive lawsuits, H.R. 9 would fundamentally alter the ability of legitimate patent holders to defend their rights. Agricultural innovation, biotechnology and sustainable agriculture will help society meet monumental challenges presented by the expected growth in demand for animal feed, food, fibers, biofuels and pharmaceuticals.  However, Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter

patent

The IP Track at BIO 2015 had a number of incredible educational sessions concerning the most relevant topics in the biotech sector. Let’s look back at what top experts in the IP field had to say about the changing nature of patentable subject matter: Panelists included: Jennifer Swan and Howard Levine, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Raul Tamayo, USPTO P. Michael Walker, E.I. du Pont de Nemours and Company Panelists focused on the increasingly restrictive interpretation of patent eligibility, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

This Independence Day, Let’s Thank the Inventors

American flag

Happy Birthday AMERICA! That’s right, this Saturday is July 4. And yes, that means what you think it means. Prepare yourself for Facebook posts of your old college roommate in an American flag t-shirt, Instagrams from your sister who makes the world’s GREATEST potato salad and texts from your cousin about prime firework viewing in D.C. (Hint: Avoid the crowds and head to the Marine Corps War Memorial and Netherlands Carillion in Rosslyn – you Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

patent

The Intellectual Property Track at the BIO International Convention was a chance for IP thought leaders in the biotech sector to discuss some of the most pressing issues impacting the industry. Let’s recap what we learned from one of the IP sessions at BIO 2015: The Impact of IPRs on (BIO)Pharma On Tuesday, patent litigation experts met to discuss inter partes review proceedings and how they are impacting biotechnology. Panelists from The Impact of IPRs Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,